Trial Profile
A randomised, double-blinded, placebo-controlled, parallel group study to investigate the safety, tolerability, pharmacokinetics and effect on synovial thickness and vascularity of 28 days repeat dosing of GW274150 or 7.5mg prednisolone in RA patients
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 27 Jun 2023
Price :
$35
*
At a glance
- Drugs GW 274150 (Primary) ; Prednisolone
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline; GSK
- 05 Jun 2007 Status changed from recruiting to completed.
- 23 Mar 2007 Status change
- 04 Sep 2006 New trial record.